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Background. In the context of sexual transmission of human immunodeficiency virus type 1 (HIV-1), current
findings suggest that the mucosal barrier is the major site of viral selection, transforming the complex inoculum to
a small, homogeneous founder virus population. We analyzed HIV-1 transmission in relation to viral and host
characteristics within the Zurich primary HIV-1 infection study.
Methods. Clonal HIV-1 envelope sequences (on average 16 clones/patient) were isolated from the first available
plasma samples during the early phase of infection from 145 patients with primary HIV-1 infection. Phylogenetic
and tropism analyses were performed. Differences of viral diversities were investigated in association with several
parameters potentially influencing HIV-1 transmission, eg, concomitant sexually transmitted infections (STIs) and
mode of transmission.
Results. Median viral diversity within env C2-V3-C3 region was 0.39% (range 0.04%–3.23%). Viral diversity
did not correlate with viral load, but it was slightly correlated with the duration of infection. Neither transmission
mode, gender, nor STI predicted transmission of more heterogeneous founder virus populations that were found
in 16 of 145 patients (11%; diversity .1%). Only 2 patients (1.4%) were assuredly infected with CXCR4-tropic
HIV-1 within a R5/X4-tropic–mixed population, as revealed and confirmed using several genotypic prediction
algorithms and phenotypic assays.
Conclusions. Our findings suggest that transmission of multiple HIV-1 variants might be a complex process
that is not dependent on mucosal factors alone. CXCR4-tropic viruses can be sexually transmitted in rare instances,
but their clinical relevance remains to be determined.
The extensive genetic diversity of human immunodefi-
ciency virus type 1 (HIV-1) is a tremendous challenge
regarding the development of broadly effective vaccines
and also for antiretroviral treatment. The genetic
bottleneck during HIV-1 transmission may be an
Achilles heel of HIV-1 [1]. The mucosal barrier could be
a key factor in driving the genetically complex viral in-
oculum to a homogeneous founder population. The
impact of the mucosal barrier may depend on the
anatomy, physiology, concurrent sexual transmitted
infections (STIs), and sexual practice [2–4]. However,
a genetic bottleneck has also been observed in in-
travenous drug users (IVDU), indicating mechanisms
independent of the mucosa [3, 5].
During transmission, there is also strong selection
for viral variants using CCR5 as a coreceptor [6, 7]. In-
depth characterization of HIV-1 tropism in larger
groups of patients during primary HIV-1 infection
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(PHI) is needed to revisit recent work reporting varying fre-
quencies of CXCR4-tropic strains during PHI [8–10]. Such data
are of particular importance, because CCR5 antagonists are
approved for clinical use mainly in salvage treatment [11, 12].
Here, we analyzed the complexity of virus populations within
the C2-V3-C3 region of the HIV-1 envelope in 145 acutely and
recently infected Zurich primary HIV-1 infection (ZPHI)-study
patients [13–17] belonging to different transmission groups
and infected with various viral subtypes. We investigated viral
and host characteristics associated with elevated viral diversity
and coreceptor tropism.
MATERIALS AND METHODS
Patient Characteristics
Patients were enrolled in the ZPHI study (http://clinicaltrials.
gov, ID 5 NCT00537966) [13–17]. Acute/recent PHI was con-
firmed in all patients according to previously published defi-
nitions [15]. We estimated a date of infection for each patient
by integrating all available clinical and laboratory data [15, 18].
During the first visit, each patient was checked for symptoms
and physical signs of concurrent STIs and serology for syphilis.
When dysuria, genital ulcers, groin, and/or rectal pain was pre-
sent, urine and/or rectal swabs were subjected to polymerase
chain reaction (PCR) analysis for Neisseria gonorrhoeae,
Chlamydia trachomatis (when positive, specific PCR for lym-
phogranuloma venereum associated L-serovars was performed),
and Herpes simplex.
Sequencing
RNA extraction, amplification, cloning, and sequencing of HIV-1
envC2-V3-C3 fragments were performed according to Rieder et al
[15] by modification of previously described methods [19, 20].
Genotypic Prediction of HIV-1 Coreceptor Usage
V3-loop sequences were interpreted by three different genotypic
prediction tools: 1) Web-PSSM http://indra.mullins.microbiol.
washington.edu/webpssm/), 2) Wetcat http://genomiac2.ucsd.
edu:8080/wetcat/v3.html), and 3) geno2phen[coreceptor] [7]
(http://coreceptor.bioinf.mpi-inf.mpg.de/index.php). We used
geno2pheno[coreceptor] with a false-positive rate of 5.75% [21].
Wetcat analysis is based on support vector machine (SVM)
classifier. Position-specific scoring matrices (PSSM) predictions
were performed by HIV-1 subtype B and C SINSI matrices for
all non-C subtypes and clade C, respectively.
Phenotyping Assays
The cell lines MT-2 (D Richman, University of California, San
Diego [22]), GHOST Parental Cell Line, and GHOST Cell
Transfectants GHOST CXCR4 and Hi-5 (VN KewalRamani and
DR Littman, New York, NY [23]) were obtained from the AIDS
Research and Reference Reagent Program (Division of AIDS,
National Institute of Allergy and Infectious Diseases, National
Institutes of Health). Syncytium-inducing phenotypes were
determined inMT-2 cell culture assays [24]. If available, primary
isolates, derived from both plasma and peripheral blood
mononuclear cells (PBMCs), were tested. In addition, GHOST
cell lines expressing CCR5 or CXCR4 and CD4 or CD4 alone
were used to determine coreceptor usage. Cells were infected
with primary virus isolates of each patient at a multiplicity of
infection of 0.06. Expression of green fluorescent protein under
control of the HIV-2 long terminal repeat promoter was de-
tected by fluorescence microscopy [25].
Phylogenetic Analyses
Sequences were edited with SeqMan-5.08 software (DNASTAR
Inc., Madison,WI), aligned withMAFFT-6.240 [26, 27], manually
corrected, and tested for hypermutations by Hypermut 2.0
www.hiv.lanl.gov). Molecular evolutionary analyses were con-
ducted using MEGA-4 [28]. Neighbor-joining phylogenetic (NJ)
trees were constructed by MEGA-4 as well as Seqboot, Dnadist,
and ‘‘neighbor and consense’’ (PHYLIP-3.68, distributed by
J Felsenstein, University of Washington, Seattle). The reference
strain HIV-1HXB2 (GenBank accession no. K03455) and other B
and non-B strains were used as outgroup references and boot-
strapping (1000 or 100 replications with MEGA-4 and PHYLIP-
3.68, respectively). Pol sequences were obtained from the Swiss
HIV Cohort study drug resistance database [29]. Pairwise dis-
tances were computed by using MEGA-4 [28]. Nucleotide di-
versities were obtained using the Tamura-Nei model. All reported
sequences have been deposited in GenBank under accession
numbers GU471280 to GU471390, GU471407 to GU471578, and
JF958169 to JF960135.
Statistical Analyses
Statistical analyses were performed using GraphPad Prism ver-
sion 5 (GraphPad Software, San Diego, CA) and STATA 11 SE
(StataCorp, College Station, TX). Nonparametric tests were
used for group comparison (Mann-Whitney U test). Multiple
linear regression was used to analyze the association of viral
diversity with viral and host baseline characteristics. The fol-
lowing variables were considered in the model: Age, sex,
transmission category, STI, acute retroviral syndrome
(ARS), viral load, CD4-cell count, viral subtype, and esti-
mated date of infection (EDI).
RESULTS
Patient Characteristics
We analyzed 145 patients comprising 131 males and 14 females
who were enrolled in the ongoing ZPHI study (Table 1). The
modes of transmission according to patients’ statements in-
cluded homosexual (73%), heterosexual (22%), bisexual (2%),
IVDU (1.4%), and others (1.4%). Concomitant STIs have been
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diagnosed in 20 patients (14%). HIV-1 subtype B was most
prevalent (80%) followed by CRF01_AE (9%), C (3%), and
A (3%). The remaining 5% of patients were infected with
HIV-1 subtypes F1, G, CRF02_AG, and CFR12_BF.
One hundred twenty-five patients were diagnosed during
documented acute HIV-1 infection. Of those, 120 patients (96%)
had an ARS [13] and 87 (70%) had a negative or in-
determinate Western blot (WB). Recent infection was di-
agnosed in 20 patients. Baseline blood samples were available
within a median of 6 weeks (range 2–18) after EDI in acute and
within 12 (range 7–24) weeks in recently infected patients.
Fiebig staging [30] was possible for 117 patients: 2 patients were
assigned to stage II, 14 patients to stage III, 52 patients to stage
IV, 20 patients to stage V, 19 patients to stage V/VI, and 10
patients to stage VI.
Phylogenetic Reconstruction
NJ trees containing clonal C2-V3-C3 sequences from 113 (78%)
patients formed individual clusters with bootstrap values of
100%. Clusters with bootstrap values ,100% were found in
32 patients, most of whom also harbored closely related pol
sequences (median genetic distance 0.0062; range 0–0.0124)
except for 4 patients forming 2 clusters. Possible contamination
was ruled out by analyzing an independent sample from each
of these 4 patients. Sequences from all patients showed no
clustering with reference clones used in our laboratory.
Validity of Viral Diversity at Baseline
In total, 2268 clones (median 16 clones/patient; range 10–16)
spanning C2-V3-C3 region of the env gene were derived from
plasma HIV-1 RNA of 145 PHI patients early after transmission
(median 6 weeks, range 2–24). The baseline viral diversities
ranged from 0.04% to 3.23% (median 0.39%). To obtain rep-
resentative samples of quasispecies, reverse transcription-PCR
was performed in duplicate using HIV-1 RNA extracts from
1 ml of plasma. The viral load of the plasma samples ranged
from 2.4 to 7.6 (median 5.3) log10 copies/ml. Despite this
broad distribution, viral loads and nucleotide diversities were
not correlated (Figure 1). The viral loads of 10 patients were
,5000 copies/ml; however, viral diversities (median 0.44%;
range 0.11–1.25%) were similar to patients with high viral loads
(P 5 .662). Thus, the sequenced clones were representative
of the actual plasma virus populations in vivo as previously
shown in chronically infected patients [20]. In addition, single
genome amplification ([SGA]median 12 sequences/sample) was
performed in a subset of 25 patients, and the resulting viral
diversities correlated well with clonal sequencing (slope 5 1.05,
intercept 5 –0.28%, r2 5 0.681; data not shown). The viral
Table 1. Baseline Characteristics of 145 Patients With Primary HIV-1 Infection
Total patients Female Acute infection Recent infection
n % n % n % n %
Number of patients 145 100 14 100 125 100 20 100
Male 131 90 112 90 19 95
Female 14 10 13 10 1 5
HIV-1 subtype Ba 116 80 5 36 99 79 17 85
Transmission mode
Homosexual 106 73 91 73 15 75
Heterosexual 32 22 14 100 28 22 4 20
Bisexual 3 2 2 2 1 5
IVDU 2 1.4 2 2
Othersb 2 1.4 2 2
STIsc 20 14 1 7 14 11 6 30
HIV-1 drug resistance transmittedd 6 4 1 7 6 5
Acute retroviral syndrome 136 94 13 93 120 96 16 80
Negative or indeterminate Western Blot 87 60 6 43 87 70
median (min-max) median (min-max) median (min-max) median (min-max)
Estimated duration of infection (weeks) 6 (2–24) 6 (2–14) 6 (2–18) 12 (7–24)
Viral load (log10 copies of HIV-1 RNA/ml plasma) 5.3 (2.4–7.6) 4.8 (4.2–6.7) 5.5 (2.4–7.6) 5.0 (3.2–6.5)
CD41 T cells (cells/ll blood) 414 (87–1295) 454 (87–1295) 374 (127–1295) 503.5 (87–965)
Age (years) 36 (19–70) 32 (19–55) 37 (19–70) 34 (20–58)
Abbreviations: IVDU, intravenous drug users; STIs, sexually transmitted infections; HIV-1, human immunodeficiency virus type 1.
a Other subtypes: CRF01_AE, C, A, F1, G, CRF02_AG, CRF12_BF.
b One case needle stick; 1 case either IVDU or heterosexual.
c Concomitant STIs: syphilis and/or chlamydia and/or gonorrhea.
d International AIDS Society-USA mutation.
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diversities increased slightly with time since EDI (EDI was de-
scribed in previously published methods [15, 18]) (Figure 2),
supporting the reliability of the EDI calculation used. As also
shown in Figure 2, negative WBs have been detected up to 10
weeks and positive WBs between 4 and 24 weeks after EDI,
demonstrating the need to include clinical data into the di-
agnostic staging process.
Viral Diversity in Relation to Host and Viral Characteristics
In our study population, the median viral diversity shortly after
transmission did not deviate among different sexual trans-
mission categories (Figure 3A). Twenty patients, including 1
female, 5 men having sex with females, and 14 men having
sex with men (MSM), were diagnosed with a concomitant STI,
but their median viral diversity did not deviate from those
without concomitant STI (P 5 .703; Figure 3B). Next, we an-
alyzed in more detail the relation between diversity and trans-
mission mode among MSM depending on the encountered
mucosa. Analyzed sexual practices were insertive anal inter-
course, receptive anal intercourse, and unsafe oral intercourse.
Patients practicing various sexual activities or with unknown
transmission route were excluded from this analysis. No sig-
nificant differences among distinct transmission modes were
observed (Figure 3C).
We also derived the viral subtypes from individual pol se-
quences to examine their possible effect on diversity (Figure 4).
Four patients had been infected with HIV-1 subtype C. They
showed a median viral diversity of 1.07% (range 0.54–1.89%),
which significantly deviated from those observed in HIV-1
subtype B (P 5 .011). In addition, no association between viral
diversity and viral tropism was found (for tropism see below).
Moreover, multiple linear regression testing the association
of viral diversity with EDI, age, CD4-cell count, viral load,
viral subtype, ARS, STI, and transmission mode showed no
relationship except for EDI (slope 5 0.031 [95% confidence
interval 5 0.001–0.061], P 5 .046, r2 5 0.151).
Characteristics of Patients With High Viral Diversity
We identified 16 subjects (11%) with a viral diversity higher
than 1% despite a short estimated duration of infection (median
7 weeks; range 4–14). Of the 14 males 3 had a concomitant STI.
One of the heterosexual men was infected either by sexual
contact or by sharing needles. For detailed patient characteristics
see Table 2. Overall, no patient’s or transmission’s characteristics
were overrepresented in the group of patients with viral diversity
higher than 1%. These patients were infected with HIV-1 sub-
type A (1 of 4, 25%), B (12 of 116, 10%), and C (3 of 4; 75%).
Phylogenetic analyses of the C2-V3-C3 region in the 16 pa-
tients with viral diversities .1% showed 3 different tree pat-
terns. In 4 patients, a starlike diversification was seen, whereas
in 8 patients the viral clones appeared to be subdivided into 2 to
4 subclusters, each with diversity below 1% and average genetic
distances between these intrapatient subgroups of 2.14% (range
1.11–4.37%). In the remaining 4 patients, a mixture of these 2
Figure 1. Relationship between plasma viral load and viral diversity
during primary human immunodeficiency virus type 1 infection. Plasma
viral load of the first available sample and the corresponding viral
nucleotide sequence diversity observed in the C2-V3-C3 region of the
envelope gene in 10–16 clones per patient is shown. One hundred forty-
five patients were analyzed. Each dot represents 1 patient. The
relationship between viral diversity and viral load is shown by linear
regression (P 5 .109; slope 5 20.299 6 0.185; r2 5 0.018).
Figure 2. Relationship between viral diversity during primary human
immunodeficiency virus type 1 (HIV-1) infection and estimated duration of
infection. For each of the 145 patients, the duration between estimated
date of infection (EDI) and first available sample and the corresponding
viral diversity observed in the C2-V3-C3 region of the envelope gene in
10–16 clones is shown. The duration of infection has been estimated
integrating all available information including patient history relating to
known risk situations, occurrence of first symptoms, previous negative
test results, avidity assays, and Western Blot (WB). The median viral
diversities increased slightly with longer time intervals between infection
and sample collection (slope 5 0.024 6 0.009; P 5 .015; r2 5 0.041).
Negative WBs were detected up to 10 weeks and positive WBs were
detected between 4 and 24 weeks of EDI, respectively. Neg WB, negative
WB; indet WB, indeterminate WB; pos WB, positive WB; n/a, not
available.
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described patterns was observed including subgroups showing
viral diversity of more than 1%.
Viral Tropism
Using PSSM, SVMwetcat, and geno2pheno[coreceptor] to predict
viral tropism in clonal C2-V3-C3 sequences, X4-tropic viruses
or R5/X4 mixed populations were predicted for 10%, 19%, and
14% of the patients, respectively (Table 3). In 102 patients
(70%), all three prediction algorithms were consistent in pre-
dicting R5-tropic viral variants. The three bioinformatic tools
yielded conflicting coreceptor usage predictions in 27% of the
patients. In 4 patients (3%), all three tools predicted X4-tropic
strains, either as a mixed population in 3 cases or as a pure
X4-tropic population in 1 case. Full-length env sequences ob-
tained by SGA showed the same quasispecies composition and
mutation patterns as clonal C2-V3-C3 sequences in these 4 pa-
tients (data not shown). Next, HIV-1 coreceptor usage was
determined by phenotypic assays using 175 available primary
isolates (from 117 patients) derived from plasma and PBMCs
(Table 4). In the first step, all isolates were screened by the MT-2
Figure 4. Influence of HIV-1 subtypes on viral diversity during primary human immunodeficiency virus type 1 (HIV-1) infection. Viral diversities observed
in the C2-V3-C3 region of the envelope gene in 145 primary HIV-1–infected patients are shown grouped according to HIV-1 subtypes. Bars indicate
medians; CRF, circulating recombinant form.
Figure 3. Influence of transmission characteristics on viral diversity during primary human immunodeficiency virus type 1 (HIV-1) infection. Viral
diversities observed in the C2-V3-C3 region of the envelope gene in 144 primary HIV-1–infected patients are shown grouped according to gender and
transmission category in A (1 patient infected by either heterosexual intercourse or needle sharing is not shown), according to the presence or absence of
a concomitant sexual transmitted infection in B, and within the transmission category men having sex with men (MSM) according to the sexual practice
during HIV-1 acquisition in C. In the latter analysis, MSM patients with unknown transmission mode or practicing several sexual behaviors were excluded
from this analysis. Bars indicate medians; MSF, men having sex with females; w/o STI, without concomitant sexually transmitted infections; STI, with
sexually transmitted infections; iai, insertive anal intercourse; rai, receptive anal intercourse; oral, unsafe oral intercourse.
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cell assay and if X4-tropism was detected, this was confirmed by
the GHOST cell assay, allowing also differentiation of mixtures
of R5/X4 double users, respectively. In 1 of the 4 patients with
concordant genotypic X4-tropism prediction and in 1 patient
with concordant CCR5-tropism prediction, a mixture of R5/
X4-tropic viruses was detected in the PBMC isolate but not in
the isolate obtained from plasma.
DISCUSSION
To investigate the complexity of transmitted HIV-1 populations,
we determined viral diversity by HIV-1 envelope C2-V3-C3
clonal sequencing and assessed potential factors associated
with transmission of heterogeneous viral populations in 145 pa-
tients enrolled in a single center primary HIV-1 infection cohort
(ZPHI study). This analysis revealed three major findings:
1) heterogeneous virus populations (diversity .1%) were
found in 11% of all patients; 2) neither concomitant STI,
gender, nor differences in sexual practices could be identified
as factors associated with transmission of heterogeneous virus
populations; and 3) genotypic prediction of coreceptor tropism
by 3 computational tools unambiguously characterized trans-
mitted viruses of 73% of all patients. Seventy percent of patients
harbored R5-tropic viruses, and 3% (4 patients) were predicted
as harboring X4-tropic and R5/X4-tropic viruses, respectively.
However, in only 1 of those, CXCR4-usage could be confirmed
phenotypically. In addition, 1 patient consistently predicted as
harboring R5-tropic viruses, showed phenotypically mixed
R5/X4-tropic viruses. Furthermore, results remained genotypically
ambiguous in 27%.
Despite various efforts [2–5, 31, 32], factors associated with
increased viral heterogeneity, which is found in 10%–20%
of PHI patients, have not been fully elucidated. However, this
Table 2. Baseline Characteristics of Patients With Higher and Lower Viral Diversity During Primary HIV-1 Infection
Viral diversity after transmission .1% ,1%
n % n %
Number of patients 16 100 129 100
Male 14 88 117 91
Female 2 13 12 9
HIV-1 subtype
Subtype A 1 6 3 2
Subtype B 12 75 104 81
Subtype C 3 19 1 1
CRF01 _AE 13 10
Transmission mode
Homosexual 10 63 96 74
Heterosexual 3 19 29 22
STIsa 3 19 17 13
Negative or indeterminate Western Blot 9 56 78 60
median (min-max) median (min-max) P value
Estimated duration of infection (weeks) 7 (4–14) 6 (2–24) .127b
Viral load (log10 copies of HIV-1 RNA/ml plasma) 5.1 (3.6–6.6) 5.4 (2.4–7.6) .623
b
CD41 T cells (cells/ll blood) 483 (127–1295) 411 (87–1120) .643b
Age (years) 32 (19–60) 36 (20–70) .403b
Abbreviations: HIV-1, human immunodeficiency virus type 1; STIs, sexually transmitted infections.
a Concomitant sexually transmitted infections: syphilis and/or chlamydia and/or gonorrhea.
b Mann-Whitney U test.
Table 3. Genotypic Prediction of HIV-1 Tropism in Patients With
Primary HIV-1 Infection
HIV-1 Subtypes All B
n % n %
Number of patients 145 100 114 100
X4 tropism prediction by:a
Geno2pheno[coreceptor]b 21 14 13 11
PSSMc 15 10 5 4
SVMwetcat 28 19 24 21
1 of 3 tools predicts X4 tropism 26 18 21 18
2 of 3 tools predict X4 tropism 13 9 6 5
3 of 3 tools predict X4 tropism 4 3 3 3
R5 tropism prediction by 3 tools 102 70 84 74
a X4 or R5/X4 mixed populations.
b Cutoff 5.75 (Prosperi et al. Retrovirology 2010, 7:56).
c Using sinsi matrix.
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result is not surprising given the difficulties to identify large
populations of well-characterized patients with PHI and the
multifactorial nature affecting diversity upon transmission.
In particular, interpretation of results may be complicated by,
1) differences in patient populations with regard to time of
sampling after infection; 2) disparities in ethnicity and living
environments such as access to health care, sanitation con-
ditions, and nutritional status; 3) potential selection bias of
patients enrolled in PHI studies; 4) uncertainties concerning
sexual practices adopted; 5) the lack of knowledge of potential
host genetic factors; and 6) different methodologies used to
investigate early transmitted virus.
Our finding of complex HIV-1 populations in 11% of patients
is in line with previous findings [2], although at a lower range.
A likely explanation for these differences might be different
frequencies of index patients transmitting a homogeneous virus
population while they are in the acute phase of their HIV-1
infection. Another potential explanation is our rather con-
servative approach, compared with others [1], to search for
complex viral populations using a cutoff of 1% diversity to dif-
ferentiate homogeneous from heterogeneous transmitted viruses.
In contrast to previous studies [3, 31–33], no elevated com-
plexity of transmitted viruses was found in the 20 patients with
a concomitant STI during PHI. STIs clearly increase the risk of
HIV-1 transmission by enhancing infectiousness and suscepti-
bility [34]. The lower viral diversity in our patients might be due
to the time of the transmission of the STI. Ongoing and already
established STIs prior to HIV-1 infection may be of higher
importance to render the mucosal barrier more susceptible for
HIV-1 infection than those transmitted concurrently with
HIV-1 or shortly thereafter. In our setting, the vast majority
of patients reported first occurrence of STI symptoms very closely
to ARS symptoms, suggesting that STIs were cotransmitted
with HIV-1. In contrast, Haaland et al [31] reported that their
Zambian and Rwandan seroconverter patients had symptoms
and signs of STIs that were already present at the time of the
last seronegative visit, suggesting that those STIs were present
for comparatively longer durations, and therefore, mucosa may
have been damaged more severely at the time of HIV-1 in-
fection. Another difference between cohorts may be the pro-
portion of female sex workers included [4]. In this group, the
prevalence of STIs and the occurrence of mucosal microtrauma
are higher than those in males or in females in general [3, 4, 35].
Female sex workers did not participate in our study.
HIV-1 subtype C may be associated with greater propensity
for transmission possibility than other HIV-1 group M subtypes
[34]. In our study, the 4 patients infected with HIV-1 subtype C
showed a higher median viral diversity compared with HIV-1
subtype B-infected patients (P 5 .011). Viral diversity of
CRF01_AE and other circulating recombinant forms were not
significantly lower compared with HIV-1 subtype B, but none
of those patients was infected with a more complex population
(.1%). Whether higher diversity seen in our HIV-1 subtype C
cases is based on HIV-1 subtype-specific viral properties or
not cannot be proven at this time. Similar diversities found in
HIV-1 subtypes B and C in other PHI cohorts question the
biological relevance of our finding [33]. However, it has to
be noted that comparisons between those 2 HIV-1 subtypes
were based on different study settings in different countries
and at different centers [33]. Thus, ultimately, only studies of
larger patient cohorts enrolled under similar conditions will
yield an answer to this question.
By combining 3 different genotypic prediction algorithms,
we found that 4 PHI patients (3%) possibly harbored CXCR4-
tropic viruses during acute HIV-1 infection. However, in only
1 of those patients, X4-tropic strains could be confirmed phe-
notypically. In addition, from 1 patient with consistent R5-
coreceptor prediction, X4-tropic strains could be isolated
within a R5/X4 mixture. Thus, in our study, transmission of
relevant replication competent X4 variants seemed to be a rare
event. These findings are in line with Raymond et al [8] who
reported 6.4% of plasma viruses as X4-tropic and R5/X4-tropic
mixtures, respectively, in patients with acute HIV-1 infection.
In contrast, a recent study using ultra-deep sequencing and
genotypic prediction reported X4-tropic variants in 50% of
a small number of patients with acute HIV-1 infection [9].
Discrepant results are not surprising given the methodological
difficulties regarding assays, prediction algorithms used, studied
populations, and sample sizes. At present, the clinical relevance
of transmitted X4-tropic minority variants is not known, be-
cause thresholds for frequencies of X4-tropic minority variants
to predict maraviroc response during PHI are not available [36].
Furthermore, the problem with genotypic prediction is that it
cannot predict replication competence of these minority spe-
cies. On the other hand, phenotypic assays using primary viral
isolates overcome this limitation but may lack sensitivity due
Table 4. Phenotypic Prediction of HIV-1 Tropism of Primary HIV-1
Isolates Obtained From Plasma and PBMCs of Primary HIV-1–
Infected Patients
Genotypea Phenotype
Number of
patients
predicted by
3 algorithms
Number of
patients
analyzed by
MT-2 assay X4 R5 R5/X4
X4 4 4 0 3 (75%) 1 (25%)b
R5 102 83 0 82 (98.8%) 1 (1.2%)c
inconsistent 39 30 0 30 (100%) 0
a Predicted by 3 bioinformatic tools: Geno2pheno, PSSM, and SVMwetcat.
b Detected in peripheral blood mononuclear cells (PBMCs) with MT-2 and
GHOST cell assay.
c Detected in PBMCs with MT-2 but not with GHOST cell assay.
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to initial selection process during their propagation in cell
cultures [37]. Recombinant phenotypic assays using PCR-
amplified HIV-1 envelope may have an improved sensitivity
profile, but they give only information on tropism of single
envelopes amplified and not on replication competence of these
viruses. Taken together, despite a considerable amount of pre-
vious work [8–10, 38, 39], frequency of clinically relevant trans-
mitted CXCR4-using viruses is still not known, but in our study
transmission of such viruses seemed to occur only rarely.
In summary, our findings suggest that transmission of complex
virus founder populations may not depend solely on mucosal
factors. In addition, transmission of clinically relevant CXCR4-
using virus strains seems to remain a rare event, and caution
is warranted when predicting coreceptor usage by genotypic
algorithms alone, because concordance of those tools is still
limited.
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